Psoriasis: Otezla (apremilast), receives European marketing authorisation in two therapeutic indications

Celgene UK has announced that the European Commission has licensed Otezla, the Company's oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic...